4.3 Review

Human Carbonyl Reductases

期刊

CURRENT DRUG METABOLISM
卷 11, 期 8, 页码 639-658

出版社

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138920010794233530

关键词

CBR1; CBR3; CBR4; metabolism; detoxification; polymorphism; regulation; endogenous substrates; xenobiotics

资金

  1. Grant Agency of Charles University [71710/C/2010]
  2. Deutsche Forschungsgemeinschaft [DFG MA 1704/5-1]
  3. [SVV-2010-261-003]

向作者/读者索取更多资源

Enzymatic carbonyl reduction means the formation of a hydroxy function out of a ketone or aldehyde moiety and applies for the metabolism of physiological (endogenous) or xenobiotic (exogenous) molecules. As for endogenous substrates, carbonyl reduction is often part of a reversible oxidoreductase process and involves the activation or inactivation of important signal molecules like steroids, prostaglandins, retinoids and biogenic amines. These reactions are carried out by NAD(P)(H)-dependent dehydrogenases belonging to two protein superfamilies, the aldo-keto reductases (AKR) and the short-chain dehydrogenases/reductases (SDR). With regard to exogenous substrates, carbonyl reduction of xenobiotics is generally a one-way detoxification reaction, since the resulting alcohol is easier to conjugate and to eliminate. Interestingly, the participating enzymes do also belong to the AKR and SDR superfamilies. Moreover, some enzymes from the two protein superfamilies exhibit pluripotency in that they are able to catalyze the oxidoreduction of endobiotics but do also function in the reductive metabolism of carbonyl group bearing xenobiotics. A special case are carbonyl reductases per se which belong to the SDR superfamily and whose substrates or physiological roles are not quite clear. Usually, carbonyl reductases have a broad and diverse substrate spectrum for xenobiotics, however, for some of them a specific physiological function has been speculated. In the human genome, three SDR genes have been identified to code for the carbonyl reductases CBR1 (SDR21C1), CBR3 (SDR21C2) and CBR4 (SDR45C1). The present review summarizes the current knowledge on these enzymes with special emphasis on their role as a defence system against toxicants, as well as their possible physiological function and medical application. In detail, we have screened the recent literature on these three enzymes with regard to endogenous and exogenous substrates, their three-dimensional structure, tissues specific expression, polymorphisms, transcriptional regulation, occurrence in pathological states, and their possible association with cancer. Combined, this review contributes to understanding the complex nature and biological role(s) of the human carbonyl reductases CBR1, CBR3 and CBR4.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Toxicology

Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile

Eva Novotna, Neslihan Bukum, Jakub Hofman, Michaela Flaxova, Etela Kouklikova, Dagmar Louvarova, Vladimir Wsol

ARCHIVES OF TOXICOLOGY (2018)

Article Biochemistry & Molecular Biology

Initial characterization of human DHRS1 (SDR19C1), a member of the short chain dehydrogenase/reductase superfamily

Lucie Zemanova, Hana Navratilova, Rudolf Andrys, Kristyna Sperkova, Jiri Andrejs, Klara Kozakova, Marc Meier, Gabriele Moeller, Eva Novotna, Miroslav Safr, Jerzy Adamski, Vladimir Wsol

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2019)

Article Pharmacology & Pharmacy

Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment

Eva Novotna, Neslihan Bukum, Jakub Hofman, Michaela Flaxova, Etela Kouklikova, Dagmar Louvarova, Vladimir Wsol

BIOCHEMICAL PHARMACOLOGY (2018)

Article Pharmacology & Pharmacy

Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters

Ales Sorf, Eva Novotna, Jakub Hofman, Anselm Morell, Frantisek Staud, Vladimir Wsol, Martina Ceckova

BIOCHEMICAL PHARMACOLOGY (2019)

Article Biochemistry & Molecular Biology

Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3

Neslihan Bukum, Eva Novotna, Anselm Morell, Jakub Hofman, Vladimir Wsol

CHEMICO-BIOLOGICAL INTERACTIONS (2019)

Article Toxicology

Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?

Eva Novotna, Anselm Morell, Neslihan Bukum, Jakub Hofman, Petra Danielisova, Vladimir Wsol

ARCHIVES OF TOXICOLOGY (2020)

Article Oncology

Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors

Ales Sorf, Simona Sucha, Anselm Morell, Eva Novotna, Frantisek Staud, Alzbeta Zavrelova, Benjamin Visek, Vladimir Wsol, Martina Ceckova

CANCERS (2020)

Article Toxicology

Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism

Anselm Morell, Eva Novotna, Jaroslav Milan, Petra Danielisova, Neslihan Bukum, Vladimir Wsol

Summary: Midostaurin, an FLT3 inhibitor, shows therapeutic benefit beyond FLT3 inhibition in treating AML by blocking AKR1C3-mediated inactivation of Dau, increasing cellular accumulation of Dau, and enhancing its cytotoxic effects.

ARCHIVES OF TOXICOLOGY (2021)

Article Oncology

Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3

Tassia S. Tavares, Jakub Hofman, Alzbeta Lekesova, Jana Zelazkova, Vladimir Wsol

CANCERS (2020)

Article Oncology

Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3

Anselm Morell, Lucie Cermakova, Eva Novotna, Lenka Lastovickova, Melodie Haddad, Andrew Haddad, Ramon Portillo, Vladimir Wsol

CANCERS (2020)

Article Pharmacology & Pharmacy

Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux

Lucie Cermakova, Jakub Hofman, Lenka Lastovickova, Lucie Havlickova, Ivona Springrova, Eva Novotna, Vladimir Wsol

Summary: This study demonstrates that the Bruton's tyrosine kinase inhibitor Zanubrutinib can counteract anthracycline (ANT) drug resistance by targeting aldo-keto reductase 1C3 (AKR1C3) and ATP-binding cassette (ABC) transporters. Zanubrutinib inhibits AKR1C3-mediated inactivation of daunorubicin (DAUN) and interferes with the efflux of DAUN mediated by ABC transporters. These findings provide a rationale for including Zanubrutinib in ANT-based therapy and suggest its potential for treating tumors expressing AKR1C3 and/or ABC transporters.

PHARMACEUTICS (2022)

Article Biochemistry & Molecular Biology

Reductive metabolism of tiaprofenic acid by the human liver and recombinant carbonyl reducing enzymes

Petra Malatkova, Adam Skarka, Katerina Musilova, Vladimir Wsol

CHEMICO-BIOLOGICAL INTERACTIONS (2017)

Article Chemistry, Medicinal

Design, Synthesis, and Biological Evaluation of Isothiosemicarbazones with Antimycobacterial Activity

Eva Novotna, Karel Waisser, Jiri Kunes, Karel Palat, Lenka Skalova, Barbora Szotakova, Vladimir Buchta, Jirina Stolarikova, Vit Ulmann, Marcela Pavova, Jan Weber, Jitka Komrskova, Pavlina Haskova, Ivan Vokral, Vladimir Wsol

ARCHIV DER PHARMAZIE (2017)

Review Neurosciences

Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors-Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment

Ondrej Soukup, Michael Winder, Uday Kumar Killi, Vladimir Wsol, Daniel Jun, Kamil Kuca, Gunnar Tobin

CURRENT NEUROPHARMACOLOGY (2017)

暂无数据